Early Phase 1 Relapsed/Refractory Clinical Trials
17 recruitingEarly Phase 1
What is a Early Phase 1 trial?
Early Phase 1 trials are the earliest stage of testing in humans. These small studies focus on how a drug is processed in the body and how it affects the body, often enrolling just a handful of participants to establish initial safety data.
Showing 1–17 of 17 trials
Recruiting
Early Phase 1
A Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.
Relapsed/Refractory Large B-Cell Lymphoma
Shenzhen Fosun Kairos Biotechnology Co., Ltd.12 enrolled6 locationsNCT07606937
Recruiting
Early Phase 1
Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis
AL AmyloidosisSystemic Light Chain AmyloidosisRelapsed/Refractory Light Chain Amyloidosis
Beijing Boren Hospital30 enrolled1 locationNCT07626476
Recruiting
Early Phase 1
A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Relapsed/Refractory B- Cell Non-Hodgkin Lymphoma
Suzhou Immunofoco Biotechnology Co., Ltd30 enrolled4 locationsNCT07376642
Recruiting
Early Phase 1
A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
Suzhou Immunofoco Biotechnology Co., Ltd30 enrolled4 locationsNCT07493135
Recruiting
Early Phase 1
A Clinical Study of AFN50 in the Treatment of Autoimmune Diseases
Relapsed/Refractory Autoimmune Diseases
Beijing Boren Hospital18 enrolled1 locationNCT07448298
Recruiting
Early Phase 1
An Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19/BCMA U CAR-T Cells in the Treatment of Relapsed/Refractory Immune-mediated Kidney Disease
Relapsed/Refractory Immune NephropathyRelapsed/Refractory Immune-mediated Kidney Disease
Changhai Hospital36 enrolled1 locationNCT07241468
Recruiting
Early Phase 1
Safety and Efficacy Study of RXIM002 in Severe, Relapsed or Refractory Autoimmune Diseases
Relapsed/Refractory B Cell-Mediated Autoimmune Diseases
Ruijin Hospital27 enrolled1 locationNCT07322718
Recruiting
Early Phase 1
A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases
Relapsed/Refractory Autoimmune Diseases
Nanjing Legend Biotech Co.36 enrolled5 locationsNCT07095075
Recruiting
Early Phase 1
Safety and Efficacy of ZZSW-01 in Relapsed/Refractory B-cell Malignancies
Relapsed/Refractory B-cell Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology6 enrolled1 locationNCT07240974
Recruiting
Early Phase 1
A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
Relapsed/Refractory Multiple MyelomaRelapsed/Refractory Plasma Cell Leukemia
The First Affiliated Hospital of Soochow University24 enrolled1 locationNCT06730256
Recruiting
Early Phase 1
A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma
Multiple MyelomaRelapsed/Refractory
The First Affiliated Hospital of Nanchang University12 enrolled1 locationNCT06999031
Recruiting
Early Phase 1
A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
Chunrui Li24 enrolled1 locationNCT06791681
Recruiting
Early Phase 1
A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy
Relapsed/refractory LymphomaRelapsed/Refractory Leukemia
Affiliated Hospital of Nantong University9 enrolled1 locationNCT06756321
Recruiting
Early Phase 1
a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia
Relapsed/Refractory Multiple MyelomaRelapsed/Refractory Plasma Cell Leukemia
Shanghai Changzheng Hospital24 enrolled1 locationNCT06718270
Recruiting
Early Phase 1
Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma
Relapsed/refractory Lymphoma
Shanghai First Song Biotechnology Co., LTD9 enrolled1 locationNCT06532643
Recruiting
Early Phase 1
Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia
Relapsed/Refractory Acute Myeloid Leukemia
Base Therapeutics (Shanghai) Co., Ltd.9 enrolled1 locationNCT06541444
Recruiting
Early Phase 1
Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia
Relapsed/Refractory Acute Myeloid Leukemia
Base Therapeutics (Shanghai) Co., Ltd.9 enrolled1 locationNCT06541405